Brokerages Set $14.00 Price Target for Ohr Pharmaceutical Inc. (OHRP)
Ohr Pharmaceutical Inc. (NASDAQ:OHRP) has been assigned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and two have given a strong buy rating to the company. Ohr Pharmaceutical’s rating score has declined by 67% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a 12-month consensus price objective of $14.00 for the company and are predicting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also given Ohr Pharmaceutical an industry rank of 156 out of 265 based on the ratings given to related companies.
Several analysts have issued reports on OHRP shares. Zacks Investment Research raised shares of Ohr Pharmaceutical from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, July 20th. Brean Capital lowered shares of Ohr Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th.
Shares of Ohr Pharmaceutical (NASDAQ:OHRP) opened at 2.86 on Monday. The firm’s market capitalization is $91.81 million. Ohr Pharmaceutical has a 12 month low of $2.44 and a 12 month high of $6.56. The stock’s 50 day moving average is $2.76 and its 200 day moving average is $2.92.
Ohr Pharmaceutical (NASDAQ:OHRP) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.03. Equities research analysts forecast that Ohr Pharmaceutical will post ($1.32) earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of OHRP. Geode Capital Management LLC raised its position in shares of Ohr Pharmaceutical by 3.9% in the first quarter. Geode Capital Management LLC now owns 152,915 shares of the company’s stock valued at $490,000 after buying an additional 5,794 shares during the last quarter. Opaleye Management Inc. bought a new position in shares of Ohr Pharmaceutical during the first quarter valued at $1,175,000. Bank of New York Mellon Corp raised its position in shares of Ohr Pharmaceutical by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 60,069 shares of the company’s stock valued at $164,000 after buying an additional 757 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Ohr Pharmaceutical during the second quarter valued at $144,000. Finally, Vanguard Group Inc. raised its position in shares of Ohr Pharmaceutical by 1.1% in the second quarter. Vanguard Group Inc. now owns 922,616 shares of the company’s stock valued at $2,528,000 after buying an additional 9,763 shares during the last quarter. 11.32% of the stock is currently owned by institutional investors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.